NCT06814119View on ClinicalTrials.gov

A Clinical Study of MK-1084 in Participants With Renal Impairment (MK-1084-010)

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 7, 2025

Primary Completion Date

November 10, 2025

Study Completion Date

November 21, 2025

Conditions
HealthyRenal Impairment
Interventions
DRUG

MK-1084

Oral tablet

Trial Locations (2)

32809

RECRUITING

Orlando Clinical Research Center ( Site 0002), Orlando

60643

RECRUITING

Research by Design ( Site 0001), Chicago

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY